相关实验视频
Updated: Mar 14, 2026

06:08
A Novel Method: Super-selective Adrenal Venous Sampling
Published on: September 15, 2017
24.4K
循环中的可溶性CXCR4无法区分原发性阿尔多斯特主义的亚型
Wanying Chao1, Yan Ren1, Mingxi Zou1
1Department of Endocrinology and Metabolism, Adrenal Center, West China Hospital of Sichuan University, Sichuan 610041, P. R. China.
Journal of the Endocrine Society
|March 13, 2026
概括
在血液中的可溶性CXC化学因子受体4型 (sCXCR4) 不反映上腺的表达或帮助确定原发性阿尔多斯特主义 (PA) 的亚型. 这种生物标志物没有诊断作用,可以区分生产阿尔多素的腺瘤和异常性过高阿尔多素症.
科学领域:
- 内分泌学 在内分泌学.
- 医疗成像医学成像
- 生物化学 生物化学
背景情况:
- 准确地确定原发性阿尔多斯特隆症 (PA) 的亚型对于有效的治疗策略至关重要.
- 上腺CXCR4表达是一种潜在的生物标志物,但其与循环水平的相关性和PA的诊断实用性仍然不清楚.
研究的目的:
- 为了研究是否血清溶性CXC化学因子受体4型 (sCXCR4) 与上腺CXCR4表达相关,通过Ga-pentixafor PET/MR测量.
- 确定sCXCR4的诊断价值,以区分生产阿尔多素的腺瘤 (APA) 和异常性阿尔多素过高症 (IHA).
主要方法:
- 160名受试者 (88名PA患者:52名APA,36名IHA;72名对照) 被纳入.
- 血清sCXCR4水平使用酶相关免疫吸收试验量化.
- 用Ga-pentixafor PET/MR来评估上腺CXCR4表达;统计分析包括组比较,相关性和ROC曲线.
主要成果:
- 血清sCXCR4水平在APA,IHA和对照组之间没有显著差异.
- 在PET/MR上发现血清sCXCR4和上腺SUV_max之间没有显著的相关性.
- 在区分APA和IHA方面,sCXCR4的诊断性能很差 (AUC为0.52).
结论:
- 循环中的sCXCR4不能准确地反映PA患者的上腺CXCR4表达.
- 血清sCXCR4缺乏用于PA亚型的诊断实用性,特别是在区分APA和IHA时.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Adrenergic Receptors: ɑ Subtype
3.2K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
3.2K
Adrenal Gland Disorders
3.7K
Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
3.7K
Adrenergic Receptors: β Subtype
4.2K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
4.2K
Antihypertensive Drugs: Direct Renin Inhibitors
1.7K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.7K
Hormonal Regulation
36.6K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
36.6K

